IHMA Publications & Posters

Poster Presentations by IHMA


  1. 2010 ASM: A Comparison of Agar Dilution Testing and Etest Strips for Anaerobes
  2. 2009 IDSA: Validity of CLSI Disk Diffusion Zone Correlates for Enterobacteriaceae versus Older Cephalosporins.
  3. 2009 IDSA: Worldwide Monitoring of Multi-Drug Resistant Clostridia (2007 – 2008): Susceptibility to Tigecycline.
  4. 2009 IDSA: Activity of Tigecycline Against Minocycline Resistance Pathogens: A Global Perspective.
  5. 2009 IDSA: In Vitro Activity of Tigecycline Against Staphylococcus aureus with Reduced Susceptibility to Vancomycin. A Global Analysis 2004-2009.
  6. 2009 IDSA: Bacteremic Fluoroquinolone Resistant Pseudomonas aeruginosa A Global in vitro comparative analysis 2004-2008.
  7. 2009 IDSA: Antibiotic Profile of 55 Carbapenem-Resistant Serratia marcescens (CRSm) – T.E.S.T. Program.
  8. 2009 IDSA: Antibiotic Profiles Against Bacteroides fragilis with Reduced Carbapenem Susceptibility – Findings of the T.E.S.T. Program.
  9. 2009 IDSA: Activity of Antimicrobial Agents Recommended for Empiric Therapy of Complicated Intra-abdominal Infections in North America 2007-2008.
  10. 2009 ICAAC: Susceptibility Rates of Anaerobic Bacteria in Six European Nations in 2007-2008
  11. 2009 ICAAC: Multi-Drug Resistant (MDR) Methicillin-Resistant Staphylococcus aureus Isolates in the U.S.
  12. 2009 ICAAC: Temporal Analysis of Tigecycline in South and Central America from 2004-2008
  13. 2009 ICAAC: The Activity of Tigecycline and Comparators in the T.E.S.T. Program 2004 - 2008
  14. 2009 ICAAC: Antimicrobial Activity of Tigecycline against Vancomycin-Resistant Enterococcus spp. - A Global Study 2004-2009
  15. 2009 ICAAC: Consistency of Activity of Tigecycline and Comparators vs. Gram-Positive Bacteria in Europe from 2004-2008
  16. 2009 ICAAC: Changes in Susceptibility of Select Non-Fermenters in Europe: 2004-2008
  17. 2009 ICAAC: In vitro Activity of Tigecycline and Comparators vs. ESBL-producing Enterobacteriaceae Globally 2004-2008 - Tigecycline Evaluation and Surveillance Trial (T.E.S.T.)
  18. 2009 ICAAC: Trends in Prevalence of ESBL+ E. coli, K. pneumoniae, and K. oxytoca in the Asia/Pacific Rim TEST Program from 2004-2008
  19. 2009 ICAAC: Trends in Tigecycline Activity against Global Respiratory Pathogens from the T.E.S.T. study, 2004 - 2008
  20. 2009 ICAAC: Comparison of Tigecycline with most Commonly-Used Antimicrobials Against Isolates Collected in Spain and Portugal including MRSA between 2004-2009
  21. 2009 ICAAC: In Vitro Activity of Tigecycline Against Recent South African Isolates from Multiple Body Sites During 2008 – 2009
  22. 2009 ICAAC: Activity of Tigecycline Against Streptococcus pneumoniae, an Important Causative Pathogen of Community Acquired Pneumonia (CAP)
  23. 2009 ICAAC: Evaluation of EUCAST and CLSI Cephalosporin Breakpoints vs. ESBL+ and ESBLE. coli, K. pneumoniae, and K. oxytoca in the SMART Study
  24. 2009 ICAAC: Global Susceptibility Patterns of E. coli from Intra-Abdominal Infections to Ertapenem and Comparators – SMART 2008
  25. 2009 ECCMID: A Multicenter Evaluation of In Vitro Activity of Oritavancin and Comparators Against Staphylococci, Enterococci and Streptococci – The ORION Study
  26. 2009 ECCMID: Trends in Susceptibility of Gram-negative Pathogens Isolated from Intra-abdominal Infections in Europe from 2003 to 2007 – The SMART Study
  27. 2009 ECCMID: Trends in Susceptibility of Gram-negative Pathogens Isolated from Intra-abdominal Infections in North America from 2003 to 2007 – The SMART Study
  28. 2009 ECCMID: An Update to a Comparison of Etest and Agar Dilution MICs for European Anaerobes – A Multi-year Analysis
  29. 2009 ECCMID: In Vitro Activity of Tigecycline Against Pathogens Isolated from Most Common Body Sites – Eastern European Data T.E.S.T. Program 2008
  30. 2009 ECCMID: Regional Variations in Penicillin Resistant Rates Against Streptococcus pneumoniae: The United States 2008
  31. 2009 ECCMID: In Vitro Activity of Tigecycline Against In-patient and Out-patient Pathogens from Centers in Pacific Rim Countries – A Multi-year Update
  32. 2009 ECCMID: Evaluation of In Vitro Activity of Tigecycline and Ten Comparators Against Methicillin-Resistant Staphylococcus Aureus from Europe: TEST Program 2004 - 2008
  33. 2009 ECCMID: Tigecycline In Vitro Activity Against Isolates of S. pneumoniae and H. influenzae: A Multi-year Update from the TEST Program in 2008
  34. 2009 ECCMID: A Comprehensive Analysis of European Data from Tigecycline Evaluation Surveillance Trials (TEST) Program, 2004 – 2008
  35. 2009 ECCMID: Susceptibility of Gram-negative/positive Pathogens Isolated in the United Kingdom and Ireland: A Multi-year Update
  36. 2009 ECCMID: In Vitro Activity of Tigecycline and Comparators Against Nosocomial Pathogens in Italy from 2004-2008
  37. 2009 ECCMID: A Multi-year Update of In Vitro Activity of Tigecycline and Commonly Used Antimicrobials Against Significant Clinical Isolates Collected from 2004 to 2008 in Belgium
  38. 2009 ECCMID: The Tigecycline Evaluation Surveillance Trial (TEST) in Canada from 2004-2008
  39. 2009 ECCMID: Antimicrobial Susceptibility of Bacteremia Pathogens in Europe (2004-2008): Results of the Tigecycline Evaluation Trial (TEST)
  40. 2009 ECCMID: Tigecycline activity against macrolide resistance in Streptococcus pneumoniae mediated by mefE and ermB determinants: A Global Analysis 2008
  41. 2009 ECCMID: Macrolide Resistance in Streptococcus Pneumoniae from the T.E.S.T. Program in Europe: A Multi-year Analysis
  42. 2009 ECCMID: Macrolide Resistance in Streptococcus pneumoniae in the United States and Canada 2004 - 2008
  43. 2009 ECCMID: Changes in Susceptibility of Select Non-Fermenters in Europe: 2004-2008
  44. 2009 ECCMID: Is the Number of ESBLs Increasing in Asia/Pacific Rim Countries? A Longitudinal Evaluation of Organisms Associated with ESBL Production between 2004-2008
  45. 2009 ECCMID: Activity of Tigecycline and Five Comparators Against Recent Gram-positive Anaerobes in Europe – The Tigecycline European Surveillance Trial
  46. 2009 ECCMID: Activity of Tigecycline Against Multi-Drug Resistant Anaerobic Isolates From Europe in 2008 – the T.E.S.T. Program
  47. 2009 ECCMID: Activity of Tigecycline Against Recent European Clinical Isolates of Clostridium difficile
  48. 2009 ECCMID: Emergence of Klebsiella pneumoniae Isolates Possessing KPC ß-lactamase in Israel, Puerto Rico, Colombia and Greece
  49. 2009 ECCMID: Detection of KPC Enzymes in Klebsiella pneumoniae Isolates from NY/NJ Sites in the TEST Program
  50. 2009ECCMID: Impact of Different EUCAST and CLSI Interpretive Breakpoints on Antimicrobial Susceptibility of Pseudomonas aeruginosa – SMART 2007
  51. 2009 ISAAR: The In Vitro Activity of Tigecycline Against Resistant Enterobacteriaceae
  52. 2009 ISAAR: The Activity of Tigecycline Against Minocycline Resistance Pathogens: A Global Perspective
  53. 2009 ISAAR: Evaluation of the Activity of Tigecycline Against Worldwide Levofloxacin-Resistant Pathogens
  54. 2009 ISAAR: The in vitro Potency of Tigecycline and Comparators Against Multidrug Resistant (MDR) Isolates: A Canadian Perspective
  55. 2009 ISAAR: An Age Analysis of the Susceptibility of Gram-positive and Gram-negative Pathogens from Centers in the Middle East: The T.E.S.T. Program (2004-2008)
  56. 2009 ISAAR: The Activity of Antimicrobial Agents Against Australian Bacteremia Isolates: The T.E.S.T. Program (2004-2008)
  57. 2009 ISAAR: Vancomycin Resistant Enterococci (VRE) in Central and South America: Antimicrobial Susceptibility
  58. 2009 ISAAR: The Antimicrobial Susceptibility of Multidrug Resistant (MDR) Acinetobacter Isolates from Latin American Countries: The T.E.S.T. Program
  59. 2009 ISAAR: The Activity of Tigecycline and Comparators to Pathogens by Infection Site Collected in the United States (2004-2008)
  60. 2009 ISAAR: Multi-year Analysis of Changes in Susceptibility Patterns for Tigecycline and Comparators in Western Europe from 2004-2008
  61. 2009 ISAAR: A Yearly Analysis of the In Vitro Activity of Tigecycline and Comparators in Asia/Pacific Rim from 2004-2008
  62. 2009 ISAAR: In Vitro Activity of Tigecycline Against Pathogens Isolated from Cerebrospinal Fluid - T.E.S.T. Program 2008
  63. 2009 ISAAR: Antibacterial Activity of Tigecycline Against Global Isolates of H. influenzae and S. pneumoniae (2004-08): T.E.S.T. Program 2008
  64. 2009 ISAAR: In Vitro Activity of Tigecycline and 10 Common Therapeutic Agents Against Methicillin-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococcus species – Global Data, 2004 - 2008
  65. 2009 ISAAR: Antimicrobial Susceptibility of Bacteremic Pathogens in Europe: Tigecycline Evaluation Surveillance Trial TEST) - 2004-2008
  66. 2009 ISAAR: Comparison of In Vitro Activity of Tigecycline and Comparators Against Pathogens from Intensive Care Patients in Europe – T.E.S.T. Program 2008
  67. 2009 ISAAR: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) – United States In Vitro Potency Against Selected Species of Enterococcus spp.
  68. 2009 ISAAR: Evaluation of Tigecycline and Comparators Against Multi-Drug Resistant (MDR) Streptococcus pneumoniae in the United States
  69. 2009 ISAAR: The 2008 Australian Tigecycline Evaluation Surveillance Trial (T.E.S.T)
  70. 2009 ISAAR: In vitro activity of Tigecycline and Comparators Against Global Isolates of Multidrug Resistant Acinetobacter Species (2004 - 2008)
  71. 2009 ISAAR: In-patient and Out-patient Enterobacteriaceae Collected from Australia – T.E.S.T. Program 2008
  72. 2009 ISAAR: Comparing Tigecycline and Comparators Against Multi-drug Resistant (MDR) Pathogens in Turkey in 2008
  73. 2009 ISAAR: Tigecycline Activity in Current (2008) Global Population – An Age Analysis: T.E.S.T. Program
  74. 2009 ISAAR: Surveillance Trends in the In Vitro Antibacterial Activity of Tigecycline in the Years 2004 to 2008 - Tigecycline Evaluation Surveillance Trial (T.E.S.T.): A Global Perspective
  75. 2009 ISAAR: In Vitro Activity of Tigecycline Against Pathogens from Switzerland, Sweden, and The Netherlands – T.E.S.T. Program 2008
  76. 2009 ISAAR: In Vitro Activity of Tigecycline Against Pathogens From France – T.E.S.T. Program 2004 – 2008
  77. 2009 ISAAR: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) – In Vitro Antibacterial Activity Against Selected Species of Non-Glucose Fermenting Gram-Gramnegative Rods – United States Data, 2004-2008
  78. 2009 ISAAR: In Vitro Potency of Tigecycline Against Methicillin Resistant and Methicillin Sensitive Staphylococcus aureus Isolates from Asia and the Pacific Rim, 2004 - 2008
  79. 2009 ISAAR: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program – An Update on the In Vitro Antibacterial Activity Against Selected Species of Non-glucose Fermenting Gram negative Rods from Asia and the Pacific Rim – 2008
  80. 2009 ISAAR: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program - Antibacterial Activity Against Enterococcus species from Asia and the Pacific Rim - 2008
  81. 2009 ISAAR: The Activity of Tigecycline and Comparators Against Fastidious Pathogens from the Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program from Asia and the Pacific Rim
  82. 2008 ICAAC: Oritavancin: Comparative in vitro Activity against Hospital-Acquired Enterococci from Multicenter Surveillance - The ORION Study
  83. 2008 ICAAC: Surveillance of Antimicrobial Activity in Acinetobacter species and Pseudomonas aeruginosa in the United States and Canada - T.E.S.T. Program 2004 - 2007
  84. 2008 ICAAC: Dealing with Acinetobacter (ACT) and Pseudomonas (PSU) in Asia/Pacific Rim (APR) Countries: A Longitudinal Evaluation of 694 ACT and 972 PSU Collected Between 2002 - 2007
  85. 2008 ICID: Bacterial Resistance Patterns of Isolates from Various Body Sites: The European T.E.S.T. Program
  86. 2008 ICID: Evaluation of 11 Antimicrobial Agents Against Australian Bacteremia Isolates: The T.E.S.T. Program
  87. 2008 ICID: Efficacy of Tigecycline Against Worldwide Levofloxacin-Resistant Pathogens
  88. 2008 ICID: Analysis of Tigecycline Activity Against Pathogens Isolated from Lower Respiratory Infections – The Global T.E.S.T. Program 2007
  89. 2008 ICID: Comparison of In Vitro Activity of Tigecycline Against Vancomycin Resistant Enterococci (VRE) in the U.S. Analyzed by CDC Regions
  90. 2008 ICID: A Profile of Tigecycline Activity Against Clinical Isolates in Spain and Portugal 2004 – 2007
  91. 2008 ECCMID: In Vitro Activity of Tigecycline and 13 Comparators against Pathogens from a Global Population of Intensive Care Patients in 2007
  92. 2008 ECCMID: In Vitro Activity of Tigecycline Against In-patient and Out-Patient Isolates from a European Population
  93. 2008 ECCMID: Comparative Analysis of Tigecycline in South America from 2004-2007
  94. 2007 IDSA: A Global Evaluation of Methicillin-Resistant Staphylococcus aureus from the T.E.S.T. Program
  95. 2007 IDSA: Changes in United States Regional Variations in Penicillin Resistant Rates Against Streptococcus pneumoniae, 1999 to 2006
  96. 2007 ICAAC: The carbapenem PZ-601 (SMP-601) has potent in vitro Gram-positive, Gram-negative and anaerobic bacterial activity.
  97. 2007 ICAAC: Changes of Susceptibility Patterns for Tigecycline and Comparators in Western Europe from 2004-2006
  98. 2007 ICAAC: Determining In Vitro Activity of 14 Antimicrobials in Asia/Pacific Rim from 2004-2006
  99. 2007 ICAAC: Evaluating Multidrug Resistant (MDR) Acinetobacter Isolates from Latin American Countries: The T.E.S.T. Program
  100. 2007 ICAAC: A Comparative Study of 14 Antimicrobials Against Vancomycin Resistant Enterococci (VRE) in Central and South America
  101. 2007 ICAAC: An Age Analysis of Gram-positive and Gram-negative Isolates from Centers in the Middle East: The T.E.S.T. Program
  102. 2007 ICAAC: The Activity of Tigecycline and Comparators to Pathogens by Body Sites Collected in the U.S. (2004-2007)
  103. 2007 ICAAC: A Comparison of the Efficacy of Tigecycline from University Hospitals in Europe and the United States
  104. 2007 ICAAC: Susceptibility Patterns of Tigecycline and Comparators in Latin America from Hospitals of Various Bed Sizes
  105. 2006 ECCMID: Tigecycline In Vitro Activity Against Multi-Drug Resistant Acinetobacter spp. In The T.E.S.T. Program Global Data
  106. 2007 ECCMID: Antibacterial Activity of Tigecycline Against H. influenzae and S. pneumoniae (2004-06) Global Population - T.E.S.T. Program 2006
  107. 2007 ECCMID: In Vitro Activity of Tigecycline Against Pathogens Isolated from Cerebrospinal Fluid - T.E.S.T. Program 2006
  108. 2007 ECCMID: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - United States In Vitro Antibacterial Activity Against Selected Species of Enterococcus spp.
  109. 2007 ECCMID: Impact of Different FDA and EU Breakpoints on Bacterial Susceptibility Patterns - Analysis of Data from the T.E.S.T Program
  110. 2007 ECCMID: Antimicrobial Susceptibility of 2,537 Bacteremia Causative Pathogens: Tigecycline Evaluation Surveillance Trial (TEST) in Europe 2004-2006
  111. 2007 ISAAR: Antimicrobial Susceptibility of 2,537 Bacteremia Causative Pathogens: Tigecycline Evaluation Surveillance Trial (TEST) in Europe 2004-2006
  112. 2007 ECCMID: Comparison of In Vitro Activity of Tigecycline against Pathogens from Intensive Care Patients in Europe - T.E.S.T. Program 2006
  113. 2007 ECCMID: Tigecycline In Vitro Activity Against Often Difficult to Treat European Pathogens
  114. 2007 ECCMID: Variable Resistance Patterns among Tigecycline and 10 Comparators against Multi-Drug Resistant Acinetobacter from the T.E.S.T.
  115. 2007 ECCMID: Patterns of Susceptibility of Gram-negatives/positives Isolated in the United Kingdom and Ireland
  116. 2007 ECCMID: Changes in United States Regional Variations in Penicillin Resistant Rates of Streptococcus pneumoniae, 1999 to 2006
  117. 2007 ECCMID: In Vitro Activity of Tigecycline and 10 Common Therapeutic Agents Against Methicillin-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococcus species - Global Data, 2004 - 2006
  118. 2007 ECCMID: Evaluation of In Vitro Activity of Tigecycline and Ten Comparators Against Methicillin-Resistant Staphylococcus aureus from 38 Countries: TEST Program 2004 - 2006
  119. 2007 ISAAR: Activity of Tigecycline Against Antibiotic Resistant Clinical Isolates of Enterobacteriaceae from the United States - The T.E.S.T. Program
  120. 2007 ISAAR: Surveillance Trends in the In Vitro Antibacterial Activity of Tigecycline in the years 2004 to 2006 -Tigecycline Evaluation Surveillance Trial (T.E.S.T.)
  121. 2007 ISAAR: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program -In Vitro Antibacterial Activity Against Selected Gram-Negative Clinical Pathogens from Asia and the Pacific Rim
  122. 2007 ISAAR: In Vitro Antibacterial Activity of Tigecycline Against Methicillin Resistant and Methicillin Sensitive Staphylococcus aureus Isolates from the Tigecycline Evaluation Surveillance Trial (T.E.S.T.) in the USA
  123. 2007 ISAAR: Evaluating Multi-Drug Resistant Acinetobacter in a Worldwide Study
  124. 2007 ISAAR: Variability of Antimicrobial Susceptibility in Isolates from Patients in Different Age Groups in the USA: 2004-2006
  125. 2007 ISAAR: Antimicrobial Susceptibility of Isolates Collected from Different Body Sites in Asia and the Pacific Rim: Tigecycline Evaluation Surveillance Trial (TEST)
  126. 2007 ISAAR: Antibiotic Activity against Vancomycin Resistant Enterococci from the Tigecycline Evaluation Surveillance Trials (TEST) Program 2006
  127. 2007 ISAAR: Tigecycline and Comparators Susceptibility Against Enterobacteriaceae of Various Resistant Phenotypes Globally
  128. 2007 ISAAR: Comparison of Antimicrobial Susceptibility of Isolates from Various Body Sites: Western European Results from Tigecycline Evaluation Surveillance Trial (TEST) 2004-2006
  129. 2007 ISAAR: Out-patient vs. In-patient Isolates from an Eastern European Population: 2004-2006 T.E.S.T.
  130. 2007 ISAAR: Global Study to Determine Antibacterial Activity of Tigecycline and Comparators Against H. influenzae and S. pneumoniae from 2004-2006
  131. 2007 ISAAR: In Vitro Activity of Tigecycline and Comparators Against Difficult-to-Treat European Isolates
  132. 2007 ISAAR: Antimicrobial Activity of Tigecycline and Comparators from Inpatient and Outpatient Pathogens in North America
  133. 2007 ISAAR: In Vitro Activity of Tigecycline Against In-patient and Out-patient Enterobacteriaceae
  134. 2007 ISAAR: In Vitro Activity of Tigecycline and 10 Common Therapeutic Agents Against Current Isolates of Staphylococcus aureus and Enterococcus Species Resistant to Other Drugs - Worldwide Data, 2006
  135. 2007 ISAAR: Tigecycline and Comparator Agents In Vitro Activity Against Recently Collected Extended Spectrum Beta-Lactamase Isolates - TEST Program
  136. 2007 ICMS: A Presentation of Global Data from Tigecycline Evaluation Surveillance Trials (TEST) Program, 2004 - 2006
  137. 2007 ISAAR: Susceptibilities of Hospital- and Community-Acquired Clinical Pathogens from Asian Hospitals: TEST Program in Asia 2006
  138. 2007 ICMS: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program - Australian Experience, 2006
  139. 2007 ICMS: The In-Vitro Antibacterial Activity of Tigecycline from an Asia/Pacific Rim Population - The T.E.S.T. Program 2006
  140. 2007 ISAAR: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - United States In Vitro Antibacterial
  141. 2006 WestPac: Patterns of susceptibility of gram negatives/positives isolated in the United Kingdom and Ireland
  142. 2006 WestPac: In vitro Activity of Tigecycline and Comparators in Belgium from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.)
  143. 2006 WestPac: In Vitro Activity of Tigecycline and Comparators Against Pathogens from Switzerland, Sweden and The Netherlands
  144. 2006 WestPac: In Vitro Activity of Tigecycline against In-patient and Out-patient Pathogens Collected From Centers in Pacific Rim Countries - T.E.S.T. Program 2006
  145. 2006 WestPac: In Vitro Activity of Tigecycline Against South African Blood, Respiratory Tract, and Urinary Tract Isolates - T.E.S.T. Program 2006
  146. 2006 WestPac: In Vitro Activity of Tigecycline Against Pathogens Isolated from Most Common Body Sites - Eastern European Data - T.E.S.T. Program 2006
  147. 2006 WestPac: Comparison of Antimicrobial Susceptibility of 1,267 Isolates from Various Body Sites: South American Results from Tigecycline Evaluation Surveillance Trial (TEST) 2004-2006
  148. 2006 WestPac: Tigecycline’s In Vitro Activity vs. Isolates from Intensive Care and Non-Intensive Care Patients - Western Europe T.E.S.T. Program 2006
  149. 2006 WestPac: North American inpatient and outpatient pathogens: Monitoring resistance in the TEST study
  150. 2006 WestPac: Susceptibilities of hospital- and community-acquired pathogens in Asia in 2006
  151. 2006 WestPac: Gender Analysis of Global Pathogen Susceptibility (2004-2006): Tigecycline vs. Comparators in the TEST Study
  152. 2006 WestPac: Tigecycline is Active Against Global Isolates of S. pneumoniae and H. influenzae: Results from the TEST Program in 2006
  153. 2006 WestPac: Tigecycline is active against Eastern European in-patient and out-patient clinical isolates
  154. 2006 WestPac: In vitro activity of Tigecycline Against Global Isolates of Multidrug Resistant Acinetobacter Species
  155. 2006 WestPac: Comparison of Antimicrobial Susceptibility of Isolates From Various Body Sites: Asia/Pacific Results From the Tigecycline Evaluation Surveillance Trial (TEST) 2004-2006
  156. 2006 WestPac: Susceptibility to Tigecycline of 23,125 Pathogens Isolated from Common Body Sites and Tissues in North America
  157. 2006 WestPac: Global Evaluation of Tigecycline and Comparators from 2004 to 2006 - Analyzed by Age
  158. 2006 WestPac: Age-Related Variances in Pathogen Susceptibilities in the USA (2004-2006): Results from the TEST Study
  159. 2006 WestPac: Tigecycline Antibacterial Activity in Current (2004-06) Western European Population - An Age Population Analysis - T.E.S.T. Program 2006
  160. 2006 WestPac: In Vitro Study to Determine the Activity of Tigecycline as Compared to Nine Comparator Antimicrobials Against Various Fastidious Isolates from the Tigecycline Evaluation Surveillance Trial (T.E.S.T.)
  161. 2006 WestPac: In Vitro Activity of Tigecycline and Commonly-Used Antimicrobials Against 1,559 Isolates Collected from 2004 to 2006 in Spain and Portugal
  162. 2006 WestPac: Activity of Tigecycline and Comparators in Nosocomial Pathogens from Italy
  163. 2006 WestPac: Bacterial pathogens in hospitalized patients in Germany: Susceptibility patterns from the TEST study
  164. 2006 WestPac: Changes in United States Regional Variations in Penicillin Resistant Rates Against Streptococcus pneumoniae, 1999 to 2006
  165. 2006 WestPac: Antimicrobial Susceptibility Of Nosocomial Pathogens in South America - Results From the Tigecycline Evaluation Surveillance Trial (T.E.S.T.) 2004-2006
  166. 2006 WestPac: In Vitro Evaluation of Tigecycline and Comparators from 2004 to 2006 - A Global Study
  167. 2006 WestPac: Comparison of Antimicrobial Susceptibility of Isolates from Various Body Sites: Western European Results from Tigecycline Evaluation Surveillance Trial (TEST) 2004-2006
  168. 2006 WestPac: In Vitro Activity of Tigecycline Against In-patient and Out-patient Enterobacteriaceae Collected from Australia - T.E.S.T. Program 2006
  169. 2006 WestPac: Evaluation of Tigecycline and Comparators in Nosocomial Pathogens from South America
  170. 2006 WestPac: Tigecycline vs. Comparators Against Multidrug Resistant Pathogens in Turkey in 2006
  171. 2006 IDSA: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - In Vitro Antibacterial Activity Against Nosocomial Pathogens in South America, 2004-2006
  172. 2006 IDSA: In Vitro Activity of Tigecycline Against 24,278 Pathogens Isolated from Common Body Sites and Tissues in North America
  173. 2006 ICAAC: Surveillance Trends in the In Vitro Antibacterial Activity of Tigecycline in the years 2004 to 2006 - Tigecycline Evaluation Surveillance Trial (T.E.S.T.)
  174. 2006 ICAAC: Tigecycline Antibacterial Activity in Current (2004-06) Global Population - An Age Population Analysis - T.E.S.T. Program 2006
  175. 2006 ICAAC: In Vitro Activity of Tigecycline Against Pathogens From France – T.E.S.T. Program 2006
  176. 2006 ICAAC: Spectrum and potency of tigecycline and comparators against nosocomial pathogens in Italy
  177. 2006 ICAAC: In vitro Activity of Tigecycline and Commonly-Used Antimicrobials Against 549 Isolates Collected From 2004 to 2006 in Belgium
  178. 2006 ICAAC: In Vitro Activity of Tigecycline Against Pathogens From Switzerland, Sweden, and The Netherlands - T.E.S.T. Program 2006
  179. 2006 ICAAC: Susceptibility of Tigecycline and Comparators in Nosocomial Pathogens from South America Hospitals: T.E.S.T. program 2004-2006
  180. 2006 ASM: An In Vitro Evaluation of Tigecycline and Ten Comparators against Methicillin-Resistant Staphylococcus Aureus Collected From a Recent Global Population: TEST Program 2006
  181. 2006 ECCMID: Tigecycline In Vitro Activity in an Out-patient vs. In-patient Global Population
  182. 2006 ECCMID: In Vitro Activity of Tigecycline and Comparators against Community and Hospital Acquired Infections In The United States - T.E.S.T. Program 2006
  183. 2006 ECCMID: Tigecycline In Vitro Activity against In-patient and Out-patient Pathogens Collected From Centers In Europe - T.E.S.T. Program 2006
  184. 2006 ECCMID: Asia and Pacific Rim Community vs. Hospital Acquired Infections - In vitro Activity Against Tigecycline and Comparators
  185. 2006 ECCMID: The In Vitro Activity of Tigecycline and 10 Comparators in a Global Population - T.E.S.T. Program 2006
  186. 2006 ECCMID: Tigecycline Antibacterial Activity in Current (2004-06) United States Pathogen Population
  187. 2006 ECCMID: Tigecycline In Vitro Activity in Current European Pathogens - T.E.S.T. Program 2006
  188. 2006 ECCMID: Extended Spectrum Beta-Lactamase Producing Enterobacteriaceae Evaluated In Vitro Against Tigecycline and Comparator Agents - T.E.S.T. Program 2006
  189. 2006 ECCMID: Tigecycline In Vitro Activity Against Often Difficult To Treat Pathogens From Centers In Asia/Pacific Rim - T.E.S.T. Program 2006
  190. 2006 ECCMID: Tigecycline In Vitro Evaluation of 1,145 Methicillin-Resistant Staphylococcus Aureus
  191. 2006 ECCMID: In Vitro Evaluation of Tigecycline Against 288 Recent Isolates of Vancomycin-Resistant Enterococci (VRE) - T.E.S.T. Program 2006
  192. 2006 ECCMID: Evaluating Tigecycline Against Cross Resistant Enterobacteriaceae in the Global T.E.S.T. Program
  193. 2006 ECCMID: Acinetobacter Resistance In Clinical Isolates from The United States Evaluated against Tigecycline and 10 Comparators
  194. 2006 ECCMID: Cross-Resistance in Clinical Isolates of Enterobacteriaceae from the United States Evaluated against Tigecycline and 10 Comparator Antimicrobial Agents
  195. 2006 ECCMID: Evaluating Cross Resistance for Enterobacteriaceae as Compared to Tigecycline For the T.E.S.T. Program in Europe
  196. 2006 ECCMID: Sampling of Staphylococcus aureus and Enterococcus species Isolates Resistant To Other Drugs Evaluated against Tigecycline- T.E.S.T. Program Global Data
  197. 2006 ECCMID: Sampling of Staphylococcus aureus and Enterococcus species Isolates Resistant To Other Drugs Evaluated against Tigecycline- T.E.S.T. Program Global Data
  198. 2006 ECCMID: Antibiotic Cross Resistance for Staphylococcus aureus and Enterococcus spp Among Tigecycline and 10 Comparator
  199. 2006 ECCMID: Multi-Drug Resistant Acinetobacter in the United States Evaluated against Tigecycline - T.E.S.T. Program 2006
  200. 2006 ECCMID: In Vitro Activity of Multi-Drug Resistant Acinetobacter against Tigecycline from the T.E.S.T. Program in Europe
  201. 2006 ECCMID: Determining Tigecycline\'s in vitro Activity Multi-Drug Resistant Enterobacteriaceae from the T.E.S.T. Program - Global Data
  202. 2006 ECCMID: In Vitro Activity Tigecycline and 10 Broad Spectrum Comparators against Multi-Drug Resistant Staphylococcus aureus: A Multi-nation Evaluation
  203. 2006 ICMS: The In-Vitro Antibacterial Activity of Tigecycline from an Asia/Pacific Rim Population - The T.E.S.T. Program 2005
  204. 2006 ICMS: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program - In Vitro Antibacterial Activity of Tigecycline at Flinders Medical Centre, South Australia
  205. 2006 ICMS: Tigecycline In-Vitro Antibacterial Activity from a Global Perspective - The T.E.S.T. Program 2005
  206. 2006 ICMS: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program - In Vitro Antibacterial Activity Against Selected Gram-Negative Clinical Pathogens from Asia and the Pacific Rim
  207. 2006 ICMS: Tigecycline in vitro Activity against Gram-Positive Pathogens and Common Resistant Phenotypes from Asia and the Pacific Rim - The T.E.S.T. Program 2005
  208. ASHP 2005: Acinetobacter Resistance In The United States: In Vitro Evaluation Of Tigecycline and Comparators Against Recent Isolates
  209. ASHP 2005: Determining Tigecycline in vitro Activity against Multi-Drug Resistant Enterobacteriaceae for the T.E.S.T. Program - United States Data
  210. ASHP 2005: Evaluating Antibiotic Cross-Resistance in Clinical Isolates of Enterobacteriaceae from the United States against 10 Antimicrobial Agents - The T.E.S.T. Program
  211. ASHP 2005: In vitro activity of Tigecycline against Multi-Drug Resistant Acinetobacter in the United States - T.E.S.T. Program 2004- 2005
  212. ASHP 2005: Tigecycline in vitro Activity against Staphylococcus aureus and Enterococcus strains Resistant To Other Drugs In The T.E.S.T. Program - United States, 2004 - 2005
  213. 2005 IDSA: Resistance Patterns of Methicillin- and Mupirocin-resistant S. aureus from Uncomplicated Skin and Skin Structure Infections (SSSIs) in the United States from March 2004–March 2005; Retapamulin Surveillance Study
  214. 2005 IDSA: Gram Positive Isolates Associated with Skin and Skin Structure Infections (SSSIs) and Collected from Sites in the United States are Highly Susceptible to Retapamulin (SB275833), a Novel Topical Antimicrobial
  215. 2005 IDSA: A Global Surveillance Program to Determine the In Vitro Activity of Tigecycline against Multi-Drug Resistant Acinetobacter spp.
  216. 2005 IDSA: A Global Surveillance to Determine Tigecycline’s In Vitro Activity against Multiple Resistant Phenotypes of Enterobacteriaceae
  217. 2005 IDSA: A Global Surveillance to Determine Tigecycline’s In Vitro Activity against Multiple Resistant Phenotypes of Enterobacteriaceae
  218. 2005 IDSA: A Global Surveillance Program to Determine the In Vitro Activity of Tigecycline against Multi-Drug Resistant Acinetobacter spp.
  219. 2005 IDSA: Determining The Anti-bacterial Activity of Tigecycline and 10 Comparators Worldwide
  220. 2005 IDSA: Determining The Anti-bacterial Activity of Tigecycline and 10 Comparators Worldwide
  221. 2005 ICAAC: The T.E.S.T. Program - Determining The Anti-bacterial Activity of Tigecycline and 10 Comparators in a Global Population
  222. 2005 ICAAC: An In Vitro Evaluation Of Tigecycline In An In-Patient vs. Out-Patient Population Worldwide
  223. 2005 ICAAC: In-Patient vs. Out-Patient In Vitro Evaluation Of Pathogens Collected From Centers In Europe
  224. 2005 ICAAC: T.E.S.T.: Validating the Activity of Tigecycline in Current European Pathogens
  225. 2005 ICAAC: Evaluation of Tigecycline Against Often Difficult to Treat Pathogens From Centers in Asia/Pacific Rim
  226. 2005 ICAAC: Multi Drug Resistant (MDR) S. aureus Are Susceptible to Tigecycline: T.E.S.T Program - United States Surveillance
  227. 2005 ICAAC: Tigecycline Antibacterial Activity in Current (2004-05) U.S. Pathogen Population
  228. 2005 ICAAC: Recently Collected Extended Spectrum Beta-Lactamase (ESBL) Isolates (354) Evaluated In Vitro Against Tigecycline and Comparator Agents: Global Perspective
  229. 2005 ICAAC: Methicillin-Resistant Staphylococcus Aureus (1,030) Collected From a Recent Global Population: Tigecycline In Vitro Evaluation
  230. 2005 ICAAC: Vancomycin Resistant Enterococci (VRE) - A Global Problem: Evaluation of Tigecycline Against Recent Isolates From Multi-Centers Globally
  231. 2005 ICAAC: In vitro Activity of Tigecycline against Multi-Drug Resistant Acinetobacter from the T.E.S.T. Program Worldwide
  232. 2005 ICAAC: Retapamulin (SB-275833), A Novel Topical Pleuromutilin, Is Active Against Community Associated Methicillin and Mupirocin-Resistant S. aureus Isolates From Uncomplicated Skin And Skin Structure Infections (SSSIs)
  233. 2005 ICAAC: Retapamulin (SB-275833), a Novel Pleuromutilin – a Multi-center Global Surveillance of Activity Against 3,797 Beta and Alpha Hemolytic Streptococci Isolated from Skin and Skin Structure Infections (SSSIs)
  234. 2005 ICAAC: In Vitro Activity of Retapamulin (SB-275833), a Novel Topical Antimicrobial, against 3721 Gram-Positive Isolates Associated with Skin and Skin Structure Infections (SSSIs) From 17 Sites in North America
  235. 2005 ICAAC: A Multi-center Global Surveillance Study of the In Vitro Activity of Retapamulin (SB-275833), A Novel Topical Pleuromutilin Against 2950 Clinical Isolates of S. aureus and Coagulase Negative Staphylococci from Uncomplicated Skin
  236. 2005 ICAAC: Tigecycline in vitro Activity against a Sampling of Staphylococcus aureus and Enterococcus species Isolates Resistant To Other Drugs in the T.E.S.T. Program Worldwide
  237. 2005 ICAAC: Tigecycline in vitro Activity against Staphylococcus aureus and Enterococcus strains Resistant To Other Drugs In The T.E.S.T. Program - United States, 2004 - 2005
  238. ACCP 2005: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - United States In Vitro Antibacterial activity Against Selected Species of Glucose Non-fermenting Organisms
  239. ACCP 2005: United States In Vitro AntibacterialActivity of Tigecycline against Methicillin Resistant and Methicillin Sensitive Staphylococcus aureus Isolates from the Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program
  240. ACCP 2005: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program - United States In Vitro Antibacterial Activity against Selected Species of Enterococci
  241. ACCP 2005: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program - In Vitro Antibacterial Activity Against Selected Species of Enterobacteriaceae in the United States
  242. 2005 ICC: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - In Vitro Antibacterial Activity Against Gram-positive and Gram-negative Pathogens in Asia and Pacific Rim
  243. 2005 ICC: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - In Vitro Antibacterial Activity against 3,935 Gram-positive and Gram-negative Pathogens in Europe
  244. 2005 ICC: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - Global In Vitro Antibacterial Activity against 14,706 Gram-positive and Gram-negative Pathogens
  245. 2005 ICC: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - In Vitro Antibacterial Activity against 9,567 Gram-positive and Gram-negative Pathogens in the United States
  246. ASM 2005: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program - In Vitro Antibacterial Activity Against Selected Species of Enterobacteriaceae in the United States
  247. ASM 2005: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - In Vitro Antibacterial Activity Against Selected Species of Enterococcus spp. - North America Data, 2004
  248. ASM 2005: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - In Vitro Antibacterial Activity against Selected Species of Non-Glucose Fermenting Gram-negative Rods - United States Data, 2004
  249. ASM 2005: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - Global In Vitro Antibacterial Activity against 14,705 Gram-positive and Gram-negative Pathogens
  250. 2005 ISAAR: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program - In Vitro Antibacterial Activity against Selected Species of non-glucose fermenting Gram negative rods from Asia and the Pacific Rim
  251. 2005 ISAAR: In Vitro Study to Determine the Activity of Tigecycline against Fastidious Isolates from the Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program from Asia and the Pacific Rim
  252. 2005 ISAAR: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program - In Vitro Antibacterial Activity against Selected Enterococcus species from Asia and the Pacific Rim
  253. 2005 ISAAR: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program - In Vitro Antibacterial Activity against Nosocomial and Community Pathogens from Asia and the Pacific Rim
  254. 2005 ISAAR: In Vitro Antibacterial Activity of Tigecycline Against Methicillin Resistant and Methicillin Sensitive Staphylococcus aureus Isolates from the Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program from Asia and the Pacific Rim
  255. 2005 ISAAR: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program - In Vitro Antibacterial Activity Against Selected Species of Enterobacteriaceae from the Pacific Rim
  256. 2005 SHEA: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - In Vitro Antibacterial Activity against 9,063 Gram-positive and Gram-negative pathogens in the United States
  257. 2005 SHEA: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - In Vitro Antibacterial Activity against 9,063 Gram-positive and Gram-negative pathogens in the United States
  258. 2005 SHEA: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program - In Vitro Antibacterial Activity Against Selected Species of Enterobacteriaceae in the United States
  259. 2005 ECCMID: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program - Global In Vitro Antibacterial Activity against Selected Species of Enterobacteriaceae
  260. 2005 ECCMID: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program - In Vitro Antibacterial Activity Against Selected Species of Enterobacteriaceae in the United States
  261. 2005 ECCMID: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program - European In Vitro Antibacterial Activity against Selected Species of Enterococci
  262. 2005 ECCMID: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program - Global In Vitro Antibacterial Activity against Selected Species of Enterococci
  263. 2005 ECCMID: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program - European In Vitro Antibacterial Activity Against Selected Species of Enterobacteriaceae
  264. 2005 ECCMID: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program - United States In Vitro Antibacterial Activity against Selected Species of Enterococci
  265. 2005 ECCMID: Microdilution Testing Methodology for Tigecycline: Addition of A Biocatalytic Oxygen-Reducing Agent May Be Required in The Absence of Fresh Media
  266. 2005 ECCMID: European In Vitro Antibacterial Activity of Tigecycline against Methicillin Resistant and Methicillin Sensitive Staphylococcus aureus Isolates from the Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program
  267. 2005 ECCMID: Global In Vitro Antibacterial Activity of Tigecycline against Methicillin Resistant and Methicillin Sensitive Staphylococcus aureus Isolates from the Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program
  268. 2005 ECCMID: United States In Vitro Antibacterial Activity of Tigecycline against Methicillin Resistant and Methicillin Sensitive Staphylococcus aureus Isolates from the Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program
  269. 2005 ECCMID: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - European In Vitro Antibacterial Activity against Selected Species of Glucose Non-fermenting Organisms
  270. 2005 ECCMID: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program - Global In Vitro Antibacterial Activity against Selected Species of Glucose Non-fermenting Organisms
  271. 2005 ECCMID: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - United States In Vitro Antibacterial activity Against Selected Species of Glucose Non-fermenting Organisms
  272. 2005 ECCMID: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - In Vitro Antibacterial Activity against Gram-positive and Gram-negative Pathogens in Asia
  273. 2005 ECCMID: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - In Vitro Antibacterial Activity against 3,686 Gram-positive and Gram-negative Pathogens in Europe
  274. 2005 ECCMID: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - In Vitro Antibacterial Activity against 9,063 Gram-positive and Gram-negative pathogens in the United States
  275. 2005 ECCMID: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - Global In Vitro Antibacterial Activity against 13,669 Gram-positive and Gram-negative Pathogens
  276. ECCMID 2005: A Comparative In Vitro Analysis of Amoxicillin-clavulanic Acid and Seven Comparative Agents in 15,499 Peadiatric Respiratory Isolates.
  277. WestPac 2004: In Vitro Study to Determine the Activity of Tigecycline as Compared to Nine Comparator Antimicrobials Against Methicillin Resistant and Sensitive Staphylococcus aureus Isolates from the Tigecycline Evaluation Surveillance Trial (T.E.S.T.)
  278. WestPac 2004: In Vitro Study to Determine the Activity of Tigecycline as Compared to Nine Comparator Antimicrobials Against Vancomycin Resistant and Sensitive Enterococcus faecium Isolates from the Tigecycline Evaluation Surveillance Trial (T.E.S.T.)
  279. WestPac 2004: In Vitro Study to Determine the Activity of Tigecycline as Compared to Nine Comparator Antimicrobials Against Various Species of Enterobacteriaceae from the Tigecycline Evaluation Surveillance Trial (T.E.S.T)
  280. WestPac 2004: In Vitro Study to Determine the Activity of Tigecycline as Compared to Nine Comparator Antimicrobials Against Various Fastidious Isolates from the Tigecycline Evaluation Surveillance Trial (T.E.S.T.)
  281. ICAAC 2004: The Effects of CO2 on the In Vitro Activity of Telithromycin when Using Etest® Compared with Broth Microdilution in 7 Reference Laboratories
  282. ICAAC 2004: Quinolone resistance in Streptococcus pneumoniae evaluated in three Asian countries during 2003-2004
  283. ICAAC 2004: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - In Vitro Antibacterial Activity Against Selected Species of Enterobacteriaceae
  284. ICAAC 2004: Microdilution Testing Methodology for Tigecycline: Addition of A Biocatalytic Oxygen-Reducing Agent May Be Required in The Absence of Fresh Media
  285. ICAAC 2004: In Vitro Antibacterial Activity of Tigecycline Against Isolates of Vancomycin-Resistant and -Sensitive Enterococcus faecium from the Tigecycline Evaluation Surveillance Trial (TEST)
  286. ICAAC 2004: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - In vitro Antibacterial Activity Against Fastidious Isolates
  287. ICAAC 2004: Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - In Vitro Antibacterial Activity Against Methicillin Resistant and Methicillin Sensitive Staphylococcus aureus Isolates
  288. ASM 2004: Comparison In Vitro Activity of Garenoxacin Against 618 Clinical Aerobes and Anaerobes Isolated from Clinical Gynecological Infections
  289. ASM 2004: Piperacillin/tazobactam MIC and Disk Correlation Study for ESBL and Non-ESBL Producing Organisms Using NCCLS Published Guidelines versus Proposed Breakpoints
  290. ICID 2004: Tigecycline In Vitro Antibacterial Activity Against 1,499 Isolates of Enterobacteriaceae
  291. ICID 2004: Tigecycline In Vitro Antibacterial Activity Against 249 Methicillin Resistant and 250 Methicillin Sensitive Staphylococcus aureus Isolates
  292. ICID 2004: Tigecycline In Vitro Antibacterial Activity Against Isolates of Non-Enterobacteriaceae
  293. ICID 2004: Tigecycline in vitro antibacterial activity against 249 methicillin resistant and 250 methicillin sensitive staphylococcus aureus isolates
  294. ECCMID 2003: Accuracy in determining telithromycin MIC values against Streptococcus pneumoniae: Haemophilus influenzae and Streptococcus pyogenes: Etest vs. Broth Microdilution
  295. ICAAC 2003: Comparison InVitro Activity of Garenoxacin (BMS-284756) Against 706 Clinical Aerobes Isolated From Complicated Skin and Skin Structure Infections
  296. ICAAC 2003: In Vitro Activity of Garenoxacin (BMS-284756) Against 465 of Clinical Anaerobes Isolated From Intra-abdominal Infections
  297. ICAAC 2003: In Vitro Antibacterial Activity of Tigecycline, a Novel Glycylcycline, Against Clinical Isolates of Enterobacteriaceae
  298. ICAAC 2003: Tigecycline, a Novel Glycylcycline with Promising Anti-Staphylococcal Activity
  299. ICAAC 2003: In Vitro Study of Tigecycline Against 776 Clinical Isolates of Non-Enterobacteriaceae From Hospitals Across Europe
  300. ASM 2003: Global Survey of In Vitro Antimicrobial Susceptibilities of Bacteroides, Prevotella, Fusobacterium, Clostridium, Eubacterium, and Peptostreptococcus Species
  301. ASM 2003: Comparison of Etest and Agar Dilution for the Susceptibility Testing of 933 Anaerobic Isolates
  302. ASM 2003: A Multi-National In Vitro Surveillance of ESBL Producers, VREF and MRSA. Results of the Pan-European Antimicrobial Resistance Using Local Surveillance (PEARLS) Study: 2001 – 2002
  303. ICAAC 2002: Regional Incidence of Extended Spectrum Beta-Lactamase (ESBL) Producing Enterobacteriaceae, Vancomycin Resistant Enterococcus Faecium (VREF), and Methicillin Resistant Staphylococcus Aureus (MRSA) from 36 Centers in 16 Countries:
  304. ASM 2002: A Recent Evaluation of In Vitro Activity of Gemifloxacin (GEM), Moxifloxacin (MOX), Gatifloxacin (GAT) and Levofloxacin (LEV) Against 2517 Streptococcus pneumoniae (SP ) Isolates Recovered From Sterile Body Sites: The FACTS Study, 2000–2001
  305. ASM 2002: Determination of Gemifloxacin (GEM), Moxifloxacin (MOX), Gatifloxacin (GAT) and Levofloxacin (LEV) Resistant Streptococcus pneumoniae (SP ) Isolates from Respiratory and Blood Sources in a Multi-center In Vitro Evaluation: The FACTS Study, 2000–2001
  306. ASM 2002: Activity of Respiratory Fluoroquinolones Gemifloxacin (GEM), Moxifloxacin (MOX), Gatifloxacin (GAT) and Levofloxacin (LEV) Against 4982 Upper and Lower Respiratory Tract Streptococcus pneumoniae (SP ) Isolates Recovered From 124 Sites in the United States
  307. ECCMID 2002: A 2001 Multi-Center, Multi-Country Surveillance Study Identifying Antibiotic Resistance To Extended Spectrum Beta-Lactamase Producing Enterobacteriaceae, Vancomycin Resistant Enterococcus Faecium and Methicillin Resistant Staphylococcus Aureus Isolates
  308. ICID 2002: Incidence Of Extended Spectrum Beta-Lactamase Producing Enterobacteriaceae (ESBL), Vancomycin Resistant Enterococcus Faecium (VREF) And Methicillin Resistant Staphylococcus Aureus (MRSA) In France Through the Pan-European Antimicrobial Resistance Using Lo
  309. ICID 2002: Checking For Incidence of Extended Spectrum Beta-Lactamase (ESBL) Producing Enterobacteriaceae, Vancomycin Resistant Enterococcus Faecium (VREF) and Methicillin Resistant Staphylococcus Aureus (MRSA) in 26 Centers from 12 European Countries: The Pan-Europ
  310. ICID 2002: Extended Spectrum Beta-Lactamase (ESBL) Producing Enterobacteriaceae, Vancomycin Resistant Enterococcus Faecium (VREF) and Methicillin Resistant Staphylococcus Aureus (MRSA): Pan-European Antimicrobial Resistance Using Local Surveillance (PEARLS) - A 2001
  311. ASM 2001: In Vitro Activity of Gatifloxacin Against Respiratory Tract Pathogens from Hospitalized Patients Isolated in 108 Sites from the United States
  312. ASM 2001: Quinolone, Beta-lactam and Macrolide Activity Against S. pneumoniae from Hospitalized Patients in the United States Irrespective of Regional Resistance Patterns
  313. ASM 2001: Comparative Activity of Gatifloxacin Against P. aeruginosa and Enterobacteriaceae Isolated from Hospitalized Patients in the United States
  314. ASM 2001: Activity of Gatifloxacin Against Penicillin-, Macrolide- and Ciprofloxacin-Resistant S. pneumoniae Isolated from Pediatric, Adult and Elderly Hospitalized Patients in the United States
  315. ICAAC 2000: In Vitro Activity of Gemifloxacin Against Multiple-drug-resistant Strains of Streptococcus pneumoniae Isolated From 42 Countries in North America, Latin America, Europe, Asia, South Pacific and Africa/Middle East
  316. ICAAC 2000: Global Resistance Patterns of Quinolones, Macrolides and b-Lactams From a Multi-center, Multi-country Study of >40,000 Isolates: The Gemifloxacin Surveillance Study
  317. ICAAC 2000: Gemifloxacin Comparative In Vitro Surveillance Study of Penicillin- and Macrolide-resistant Pneumococci and other Respiratory Pathogens in Asian and Pacific Rim Countries
  318. ECCMID 2000: Gemifloxacin Demonstrates Potent In Vitro Activity Against Global Isolates of Antibiotic-resistant Streptococcus pneumoniae
  319. ASM 2000: In Vitro Activity of Gemifloxacin Against Enterobacteriaceae Isolated in North America
  320. ASM 2000: Activity of Gemifloxacin (SB-265805) Against Penicillin-, Macrolide- and Ciprofloxacin-resistant Streptococcus pneumoniae Isolated in the United States, Canada and Europe
  321. ASM 2000: A Global Comparative In Vitro Surveillance Study of Gemifloxacin Against